Drug Combination Details
| General Information of the Combination (ID: C52194) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | 2-methoxyestradiol Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Urothelial cancer
[ICD-11: 2C9Z]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SV-HUC-1 | CVCL_3798 | Healthy | Homo sapiens | ||
| NTUB1 | CVCL_RW29 | Bladder carcinoma | Homo sapiens | |||
| T24 | CVCL_0554 | Bladder carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
2-Methoxyestradiol Induces Mitotic Arrest, Apoptosis, and Synergistic Cytotoxicity with Arsenic Trioxide in Human Urothelial Carcinoma Cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | 2-methoxyestradiol induces mitotic arrest, apoptosis, and synergistic cytotoxicity with arsenic trioxide in human urothelial carcinoma cells. PLoS One. 2013 Aug 13;8(8):e68703. | |||
